Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2009

Trevena to Use Ligand’s Library to Identify GPCR Therapeutics

  • Ligand Pharmaceuticals and Trevena initiated a joint research and license alliance related to G-protein coupled receptor (GPCR) therapeutics. Trevena’s platform will be used to screen targets against Ligand’s combinatorial library of compounds.
     
    Under the terms of the agreement, Trevena has been granted exclusive, worldwide rights to sublicense active compounds resulting from the collaboration. Ligand expects to screen 24 targets over two years and receive payments triggered by a tiered screening paradigm for each target.

    “We are delighted to enter into this collaboration that allows us to generate cash flow from the combinatorial chemistry technology we gained through our acquisition of Pharmacopeia,” says John L. Higgins, president and CEO of Ligand. In September 2008, Ligand offered to buy Pharmacopeia for $55 million.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »